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Background: Patients with cystic fibrosis (CF) are at high risk from the nephrotoxic effects of intravenous antibiotics due to repeated and
prolonged courses of therapy. Routine methods of monitoring renal injury are insensitive. N-acetyl-b-D-glucosaminidase (NAG) is a
lysosomal enzyme present in the renal proximal tubular cells, with increased excretion an indicator of renal tubular dysfunction.
Methods: UrinaryNAG, creatinine, serum creatinine, electrolytes andBUNweremeasured on days 1, 14 and at the first out-patient visit following
treatment with tobramycin or colistin. Urinary NAG levels were corrected for urinary creatinine and expressed as a NAG ratio. Patients who
received >1 course of intravenous antibiotics during the study period were included in a separate analysis of the cumulative effect of treatment.
Results: 88 patients (44 female, 31 with CFRD) completed a single course of intravenous antibiotics. 71 patients had urinary NAG levels at
follow-up. The median time to follow-up was 50 days. Serum electrolytes, creatinine and BUN were normal throughout. A 3.5-fold increase
in urinary NAG excretion was observed between day 1 and 14 and 46% of patients had an elevated NAG level at follow-up. A highly
significant difference in NAG excretion was observed on day 14 for tobramycin vs. colistin (median 2.24 vs. 0.98, p<0.001). A significant
difference in NAG excretion was seen in patients with CFRD at all measured time points. Patients with CFRD had a significantly worse
clinical status and had received more days of intravenous antibiotics over the previous 6 years. In 20 (80%) of 25 patients who received >1
course of treatment during the study period, baseline NAG levels were significantly higher in subsequent courses (p<0.001). There was a
significant correlation between previous exposure to colistin and baseline NAG levels (r=0.389, p<0.001).
Conclusions: Both tobramycin and colistin cause acute renal tubular injury with a significant rise in urinary NAG excretion. Patients with
CFRD seem to be at greatest risk of renal tubular damage. Cumulative damage is evident with repeated dosing. Previous exposure to
nephrotoxic antibiotics, especially colistin, is associated with elevated baseline NAG levels. We recommend that colistin is reserved for
patients with resistant Pseudomonas aeruginosa or those who are intolerant to tobramycin. Serial longitudinal NAG measurements may be
useful in patients with CF, especially those with CFRD, to identify patients at risk of developing renal disease.
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Median age of survival for patients with cystic fibrosis
(CF) has increased to 35 years [1], with just over half⁎ Corresponding author. Tel.: +44 113 2063513.
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doi:10.1016/j.jcf.2006.05.013(50.8%) the patients in the United Kingdom over the age of
16 years [2]. It is therefore important to screen for non-
pulmonary complications that may threaten longevity and
quality of life. Patients with CF are exposed to repetitive and
often prolonged courses of therapy with aminoglycosides
and other nephrotoxic antibiotics. Cases of acute renal failure
(ARF) have been reported in children [3–6], adolescents
[7,8] and adults [9]. Al-Aloul and colleagues have recentlyed by Elsevier B.V. All rights reserved.
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impairment in clinically stable adults using creatinine
clearance as an index of renal function [10].
Current monitoring for renal injury (blood urea nitrogen
(BUN), serum creatinine) is not sufficiently sensitive to
detect early changes in renal tubular function. Toxicity is not
detected until serious functional damage is evident with a
large reduction in nephron mass. The primary toxic effect of
aminoglycosides is on the lysosomal system within the
proximal tubule. N-acetyl-b-D-glucosaminidase (NAG) is a
lysosomal enzyme present in high concentrations in the
proximal tubular cells. Its molecular weight (140 kDa) does
not permit glomerular filtration. Raised urinary NAG levels
have been shown to reflect renal tubular dysfunction [11–15].
Only five studies havemeasured urinary NAG excretion during
intravenous aminoglycoside antibiotic therapy in patients with
CF [16–20]; this is the first study to assess the effects of both
tobramycin and colistin on renal tubular function.
The aim of this study was to prospectively investigate the
effect of nephrotoxic antibiotics on renal tubular function in
adult patients with CF, with the measurement of urinary NAG
before, during and after a course of intravenous antibiotic
therapy. Secondary aims were to examine the relative
nephrotoxicity of tobramycin and colistin sulphomethate
(colistin), to assess if patients with cystic fibrosis related
diabetes (CFRD) are at increased risk of renal damage and to




Patients attending the Regional Adult CF Unit at Seacroft
Hospital commencing a course of treatment with intravenous
antibiotics (elective/exacerbation) were eligible for enrol-
ment into the study. All patients required an established
diagnosis of CF≥ (sweat chloride >60 mmol/L or genotype
known to cause the disease). Patients were eligible if aged
over 16 years and chronically colonised with Pseudomonas
aeruginosa [21]. Exclusion criteria were a known allergy to
intravenous tobramycin or colistin, pre-existing renal
impairment (BUN or serum creatinine outside the reference
range), post transplantation or treatment with immunosup-
pressive therapy. Female patients were offered a pregnancy
test before entry and excluded if test results were positive.
CFRD was diagnosed using the revised World Health
Organisation (WHO) criteria [22]; symptoms of hyperglycae-
mia plus either random glucose concentration≥11.1mmol/l or
fasting glucose ≥7.0 mmol/l or 2 h plasma glucose
≥11.1 mmol/l following an oral glucose tolerance test
(OGTT). All patients gave informed consent and ethical
approval for the study was obtained from the Leeds East
Research Ethics Committee. Patients who had already
consented to the study were eligible to be enrolled on
subsequent admissions.2.2. Study procedures
All patients received two intravenous anti-pseudomonal
antibiotics for 14 days including either colistin at a dose of
2 MU t.d.s if weight >40 kg (1MU t.d.s. if <40 kg) or
tobramycin as a single daily dose of 10 mg/kg/day. A second
anti-pseudomonal antibiotic (ceftazidime, meropenem, aztreo-
nam or tazocin) was administered according to in-vitro
sensitivity results and patients' allergy status. The doses of
these antibiotics were within the UK guidelines [23]. Treatment
was given either in hospital or at home, in accordance with unit
protocols. Nebulised antibiotics were discontinued during
intravenous therapy. Time to first out-patient visit following
treatment was documented. According to local protocols,
serum trough tobramycin levels were measured immediately
before the 2nd dose and again in the second week (8th dose) to
achieve a trough level of <1 mg/L. Serum electrolytes,
creatinine and BUN were measured on days 1, 14 and
follow-up by routine clinical laboratory methods. Hospital
records were examined to obtain both the time interval from the
preceding course of intravenous antibiotic therapy and the total
number of days of intravenous antibiotics (colistin and
tobramycin) for each patient for a 6 year period prior to the
study. For patients with CFRD, hospital records were examined
to obtain information on demographics, age at onset of CFRD,
duration of CFRD and level of glycosylated haemoglobin
(HbA1C). Diabetic nephropathy was assessed using urinary
albumin–creatinine ratio; microalbuminuria was defined as an
albumin–creatinine ratio greater than or equal to 2.5 mg/mmol
(men) or 3.5mg/mmol (women) [24]. Patientswho received>1
course of intravenous antibiotics during the study period
were included in a separate analysis on the cumulative effect of
treatment.
2.3. Measurement of urinary NAG and creatinine
Random mid-stream urine specimens were obtained on
day 1 (prior to commencement of therapy), day 14 and at 1st
visit to the out-patient clinic following treatment. Urinary
NAG was assayed by spectrophotometry; 2-Methoxy-4(2-
nitrovinyl)-phenyl 2 acetamido-2-deoxy-b-D-glucopyranoside
(MNP-GLcNAc) is hydrolysed by NAG with the release of 2-
Methoxy-4-(2-nitrovinyl)-phenol. On addition of an alkaline
buffer (pH 9.5) a red colour is producedwhich can bemeasured
at 505 nm [25,26]. Urine creatinine was measured by the Jaffe
reaction; creatinine reacts with picrate ions in an alkaline
solution to form a red tautomer of creatinine picrate [27]. This
reaction was then quantitated spectrophotometrically at 500–
530 nm. Both urinary NAG and creatinine assays were
performed on Roche Mira S [28]. To minimise the effect of
varied urine concentration, urinaryNAG activitywas corrected
for by urinary creatinine and expressed as a NAG ratio. The
normal range of the NAG ratio in adults is 0.12–0.47 μmol/
min/mmol creatinine [25]. This range was used for the current
study, although no parameter has been defined for the CF
population.
Table 2
Median (range) urinary NAG excretion for tobramycin vs. colistin
Urinary NAG excretion of colistin vs. tobramycin









0.29 (0.04–2.32) 2.24 (0.44–21.97) 0.36 (0.09–1.54)
(0.21, 0.41) (1.50, 3.10) (0.28, 0.54)
Colistin
[n=53]
0.45 (0.01–3.75) 0.98 (0.29–9.07) 0.48 (0.01–2.77)
(0.32, 0.51) (0.78, 1.21) (0.39, 0.57)
p=0.087 *p<0.001 p=0.382
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Data are presented as median and range for metric
variables, and proportions (%) for categorical variables. As
urinary NAG measurements were not normally distributed,
non-parametric tests were used throughout. Estimates of the
differences between groups were expressed as medians and
95% confidence intervals. The results of the studied groups
(medians) were compared using the Mann–Whitney U-test.
Proportions were compared using Chi-squared test (χ2).
Kruskal–Wallis one-way analysis of variance was used to
compare 3 or more groups. Spearman's rank correlation
coefficient was calculated for the association between
continuous variables. The relationship between baseline
NAG and previous intravenous antibiotic use was examined
using linear regression. Wilcoxon Signed Rank test was used
to examine paired baseline NAG data in patients receiving >1
course of treatment A p value of <0.05 was considered
significant. Analysis was performed using Minitab, version
14.0.
3. Results
Eighty-eight patients (44 female, 31 with CFRD (35%))
completed a 14 day course of treatment, 35 with tobramycin
(40%) and 53 with colistin (60%), The median (range) age of
the study population was 24.9 (17.5–44.6) years, with forced
expiratory volume in 1 second (FEV1) 41 (12–96) %
predicted normal, forced vital capacity (FVC) 68 (28–138)
% predicted normal and body mass index (BMI) 20.1 (15–
31.4) kg/m2. No patient had a history of pre-existing renal
disease and all had normal BUN and serum creatinine levels
prior to the start of the study. Seventy one patients (81%) had
a follow-up urinary NAG level, at a median time of 50 days
(range 8–143, 95% CI (42, 58)) post treatment. Seventeen
patients (19%) did not have a follow-up urinary NAG level
(patient refusal).
Urinary NAG excretion, BUN and serum creatinine on
days 1, 14 and at follow-up for all treatment courses areTable 1
Median (range) urinary NAG excretion and BUN/serum creatinine on day 1,
14 and at follow-up for all treatment courses
Urinary NAG and BUN/serum creatinine levels for all treatment courses











0.37 (0.01–3.75) (0.30, 0.48) 3.7 (0.8–7.4) 67 (31–99)
Day 14
[n=88]
1 . 2 8 ( 0 . 2 9 –
21.97)
(0.98, 1.68) 4.4 (2.0–9.3) 69 (33–117)
Follow-up
[n=71]





Normal ranges for BUN (2.1–8.0 mmol/L) and creatinine (70–100 mmol/L).shown in Table 1. A 3.5-fold rise in urinary NAG excretion
was observed between day 1 and day 14, which returned to
baseline at follow-up. All trough tobramycin serum levels
were <1 mg/L. Serum electrolytes were normal throughout
(data not presented).
Although the median value of NAG at baseline was
normal, 36 patients (41%) had an elevated level. There was a
highly significant difference in the proportion of those with
elevated NAG at baseline in patients with and without CFRD
(77% vs. 21%, χ2 =22.64, p<0.001). By day 14, 10 patients
failed to show an increase in NAG above the upper range of
normal (11.4%); 8 of these did show an increase from
baseline but not above the normal range. Only 2 patients
(2.3%) in the study population failed to show any rise in
urinary NAG with intravenous antibiotic therapy. At follow-
up, although the median value of NAG was normal, 33
patients (46%) had an elevated level at follow-up. There was
a significant difference in the proportion with an elevated
NAG at follow-up in patients with and without CFRD (76%
vs. 30%, χ2 =10.47, p<0.01).
The effects of tobramycin and colistin on urinary NAG
excretion are shown in Table 2. On day 14, a highly significant
differencewas observed between tobramycin and colistin (2.24
vs. 0.98, p<0.001). For patients receiving tobramycin, there
was an 8-fold increase in NAG at day 14, compared to a 2-fold
increase for patients receiving colistin (see Fig. 1). The follow-Fig. 1. Comparison of urinary NAG levels between colistin and tobramycin.
Table 3
Median (range) urinary NAG excretion for patients with and without CFRD
Effects of CFRD on urinary NAG excretion









0.58 (0.13–3.75) 1.99 (0.45–21.97) 0.64 (0.17–1.41)
(0.53, 0.81) (1.03, 3.00) (0.50, 0.79)
Non-CFRD
[n=57]
0.29 (0.01–2.31) 1.05 (0.29–9.95) 0.36 (0.01–2.77)
(0.26, 0.35) (0.77, 1.50) (0.29, 0.43)
*p<0.001 *p=0.021 *p=0.004
Table 4
Demographic data CFRD vs. non-CFRD patients
CFRD (n=31) Non-CFRD (n=57)
Proportion female 21/31 (68%) 23/57 (40%) *p<0.0001
Age (years) 30.2 (18.8–41.7) 24.2 (17.5–44.6) *p=0.002
BMI (kg/m2) 20.1 (16.2–25.9) 20.3 (15.0–31.4) p=0.477
FEV1 (%pred.) 35 (12–73) 47 (15–96) *p=0.041
FVC (%pred.) 62 (28–122) 70 (28–138) p=0.085
Previous days iv
tob/colistin
266 (98–490) 154 (0–392) *p<0.0001
Previous days
iv colistin
196 (0–462) 56 (0–330) *p=0.0001
Previous days
iv tobramycin
70 (0–196) 42 (0–238) p=0.230
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colistin, but returned to baseline following tobramycin. There
was no significant difference in the median time to follow-up
between those who received tobramycin or colistin (52 (8–
123) days vs. 48 (11–143) days, p=0.237).
Thirty-eight patients (43%) received ceftazidime as a sec-
ond antibiotic, 26 aztreonam (30%), 19 tazocin (21%) and 5
meropenem (6%). There were no significant differences in the
proportions of second antibiotics administered with either
tobramycin or colistin, or in those with or without CFRD. A
comparison of day 14 NAG levels vs. second antibiotics
revealed no significant difference between the 4 groups,
p=0.138.
Thirty-one patients had CFRD (35%). The diagnosis of
CFRD was made at a median (range) age of 19 (12–34)
years, with duration of CFRD of 7.2 (2.4–23.5) years.
Median HbA1C was 6.7 (4.6–12.5) % [normal range 4.4–
6.2%]. Table 3 shows the difference in median urinary NAG
excretion in those with and without CFRD. There was a
highly significant difference at all measured time points.
Both groups showed a similar 3.5-fold increase in NAG from
baseline with treatment (Fig. 2), although those with CFRD
had a significantly higher baseline level. The demographics
of patients with CFRD are shown in Table 4. CFRD was
associated with increasing age and female preponderance.Fig. 2. Comparison of urinary NAG levels in patients with and without
CFRD.These patients had a significantly lower FEV1 and had
received more days of intravenous antibiotics (colistin> to-
bramycin) over the previous 6 years, compared to those
without CFRD. There was no significant difference in the
proportion of tobramycin (42% vs. 39%, χ2 =0.05, p>0.1) or
colistin (58% vs. 61%, χ2 =0.05, p>0.1) received between
the two groups, or in days to follow-up (CFRD 47(8–125)
days vs. non-CFRD 53 (12–143) days, p=0.406). Although
there was a trend to a shorter time interval from the preceding
course of treatment in patients with CFRD 69 (16–200) days
vs. 93 (16–501) days, the difference was not significant,
p=0.585. In patients with CFRD there was no significant
correlation between baseline NAG levels and either HbA1C
(r=0.286, p=0.119) or duration of CFRD (r=0.131, p=0.481).
Twenty-two patients with CFRD (71%) had data on albumin–
creatinine ratio at the time of the current study. The median
(range) for females was 2.5 (0.6–21.6) mg/mmol and for males
1.0 (0.4–3.2) mg/mmol; both of these within the normal ranges.
Twenty-five patients (7 with CFRD, 28%) received more
than 1 course of treatment during the study period; 15
received 2 courses and 10 received 3 courses. Within-patient
comparison of baseline NAG levels between the first and
second treatment revealed a successive rise in 20/25 patients
(80%), p<0.001. Themedian time interval to second treatment
was 65 days (range 38–150, 95%CI (48, 84)). Of the 10Fig. 3. Correlation between baseline NAG and previous days exposure to
colistin (r=0.389, p<0.001), y=0.284+0.0013x.
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revealed a further consecutive rise at baseline between the
second and third treatment, p=0.028.
The total number of days of intravenous antibiotics
received over a 6 year period prior to the start of the study
was available in 84 patients; 4 patients received their first
course of intravenous antibiotics during the study. Colistin
accounted for 63% of all days of prescribed treatment, and
tobramycin 37%, similar proportions to those received for
the single course of treatment. There was a significant
association between previous antibiotic exposure and
baseline NAG levels (r=0.375, p<0.001). When colistin
and tobramycin were analysed separately, the association
was significant for colistin (r=0.389, p<0.001, Fig. 3), but
not for tobramycin (r=0.024, p=0.822).
4. Discussion
This study shows significant elevation of urinary NAG
levels following administration of both tobramycin and
colistin. It is reassuring that the non-diabetic population had
normal baseline and follow-up NAG levels. Patients with
CFRD seem to be at greatest risk of antibiotic associated
nephrotoxicity, following both short and long term exposure
to antibiotics. Cumulative damage was evident with repeated
courses of treatment.
Aminoglycosides are a common cause of renal injury in
patients with CF, although immunosuppressive treatment
following lung transplantation may also result in significant
renal impairment [29]. CF patients are at high risk for
aminoglycoside nephrotoxicity due to high dosage, prolonged
therapy, cumulative exposure, dehydration, concurrent neph-
rotoxic medication and pre-exiting renal disease [30].
Aminoglycosides target the lysosomal system within the
proximal tubule. The drug initially binds to the brush border
membranes and is then transferred to the tubular cell
lysosomes, which may subsequently leak and rupture.
Advanced toxicity is characterized by tubular cell necrosis
and eventually renal failure [31]. Despite significant urinary
NAG excretion in this study, routine indices of renal function
remained normal. Since completion of the study, four patients
with CFRD and the highest NAG levels at baseline have
subsequently developed renal impairment with functional
elevation of BUN and serum creatinine. Persistent elevation of
NAG levels may thus predict the development of renal
impairment in CF and serve as a prognostic indicator.
There have been few previous studies assessing urinary
NAG excretion in patients with CF during intravenous
treatment. Reed et al. [16] reported an elevation of urinary
NAG excretion in 12 of 13 treatment courses with either
intravenous gentamicin or tobramycin. Steinkamp et al. [17]
reported a significant increase in mean urinary NAG excretion
in 10 patients treated with intravenous tobramycin, which was
reversible 4–120 days following treatment. Godson et al. [18]
assessed urinary NAG activity on 4 adult patients who
received intravenous gentamicin and reported a significantincrease in enzymuria in all patients; but did not state if levels
returned to baseline following treatment.
The above studies were performed on small numbers of
patients and were reported between 1981 and 1988. A recent
study by Glass et al. [19] reported a reversible increase in
urinary NAG excretion following 2 weeks of intravenous
tobramycin in 22 children with CF. Increasing numbers of
patients now survive to adulthood. The present study cohort
represents an older group of patients with moderately severe
lung disease who have received multiple courses of treatment
with nephrotoxic antibiotics. Our results have shown the
increase in NAG excretion to be reversible following
treatment; only the non-diabetic group having normal
baseline and follow-up levels.
The follow-up time interval is very wide (8 to 143 days),
but the confidence interval for this value is very narrow (95%
CI (42, 58) days) suggesting a precise estimate of the median
time to follow-up. There was no significant correlation
between the time interval to follow-up and the value of NAG
at follow-up. In addition, no patient received any further
intravenous antibiotics during this time period. Seventeen
patients (19%) did not have follow-up data for analysis
(patient refusal). Six of these had CFRD (35%), 11 received
colistin (65%) and 6 tobramycin (35%); all these proportions
are not significantly different to those in the whole study
population and thus those without follow-up data would not
have significantly affected the results.
The proportions of different second antibiotics prescribed
in the study population did not differ significantly between
those who received tobramycin and colistin, or in those with or
without CFRD. The combination of aminoglycosides and
ceftazidime has recently been reported to increase the risk of
nephrotoxicity in CF patients. Stephens et al. [6] reported four
cases of ARF in patients following commencement of
treatment with intravenous gentamicin and ceftazidime; 3
cases showed acute tubular necrosis (ATN) on biopsy. Of a
further six cases of ARF in patients treated with the same
antibiotic combination [4,5], 4 patients who underwent renal
biopsy all showed ATN. Ceftazidime has a dose related toxic
effect on the renal tubules, similar to aminoglycosides,
associated with enzymuria [32]. No patient in our study
developed ARF, and a comparison of day 14 NAG levels
according to the second antibiotic administered revealed no
significant difference. The possibility of an additional effect on
urinary NAG excretion due to antibiotics other than tobramycin
or colistin cannot, however, be completely excluded.
Due to the emergence of multi-resistant strains of P.
aeruginosa, colistin is now increasingly used for the treatment
of respiratory exacerbations. Significant changes in BUN and
creatinine clearance with colistin in CF have been reported, but
at 24month follow-up, no adverse consequences were detected
[33]. The largest study to date analyzed 2414 patient days of
intravenous colistin; no significant changes in BUN or serum
creatinine were observed with treatment [34]. The pharmaco-
kinetics of colistin sulphomethate have been reported [35], but
the mechanism of renal damage is unknown. The present study
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compared to an 8-fold rise with tobramycin. The acute tubular
injury following tobramycin seems to be reversible with a
return to normal level at follow-up. Following colistin, there
was evidence of incomplete resolution of renal tubular damage
which could not be explained by a difference in time to follow-
up between the two groups. The present study is the first to
show subclinical evidence of renal impairment directly due to
colistin.
Previous exposure to intravenous antibiotics (tobramycin
and colistin) in our study showed a strong correlation with
elevated baseline NAG levels. When analyzed separately the
association was only significant for colistin. This may reflect
the greater use of colistin in our unit (colistin 63%, tobramycin
37%) over the 6 year period or the fact that colistin is more
likely than tobramycin to cause tubular dysfunction. These
findings are in contrast to those of Al-Aloul et al. [10] who
demonstrated a strong correlation between lifetime intravenous
aminoglycoside use and reduced renal function which was
potentiated by the coadministration of colistin and tobramycin.
On its own, colistin did not appear to be nephrotoxic. The
TOPIC study has shown that aminoglycosides may be less
nephrotoxic when given once daily [20]. They reported a
smaller rise (33% less) in urinaryNAG excretion for 107 adults
and children who received once daily tobramycin compared to
three times daily. Single daily dosing of aminoglycosides has
been our unit policy since 1999, and may have afforded some
protection against nephrotoxicity secondary to tobramycin in
our study population [36].
Diabetes is associated with significantly higher levels of
urinary NAG excretion in patients without CF [37]. Al-Aloul
et al. showed no difference in the prevalence of CFRD
between those with and without renal impairment [10]. This
study has shown a significant elevation in urinary NAG
excretion in patients with CFRD, and is the first study to show
elevated baseline NAG levels in any patient with CF. The
higher baseline levels in patients with CFRD could not be
explained by the level of glycaemic control, the duration of
CFRD or the time interval from the preceding course of
treatment. There was no evidence of diabetic nephropathy,
although complete data were not available in all patients. The
increased baseline levels in patientswithCFRDmay reflect the
fact that they were older, predominately female, with a
significantly lower FEV1, and had received significantly more
days of antibiotics than the non-diabetic group.
A similar 3.5-fold increase in urinary NAG excretion
from day 1 to day 14 was seen in both those with and without
CFRD, despite the different baseline levels, confirming the
absence of diabetic nephropathy in the CFRD group. The
follow-up level in the CFRD group remained significantly
elevated. This difference was not due to a shorter time to
follow-up in these patients, and probably reflects the greater
disease severity and greater exposure to intravenous
antibiotics in this group. Over 30% of adults have CFRD,
and it is estimated that 30–50% of these patients will develop
diabetic nephropathy within 5–10 years of diagnosis [38].In conclusion, urinary excretion of NAG was significantly
elevated following a single course of treatment with either
tobramycin or colistin, with abnormal values persisting at
follow-up in some patients. It is reassuring that most patients
with CF without CFRD had normal baseline and follow-up
NAG levels. Patients with CFRD appeared to be a more
severely affected group, with elevated baseline and follow-up
levels. Nonetheless, in this groupNAG levels did return to pre-
treatment values at follow-up. Cumulative damage is evident
with repeated dosing. Greater exposure to nephrotoxic
antibiotics, especially colistin, over a 6 year period was
associated with a greater degree of renal tubular dysfunction.
We recommend that colistin is reserved for patients with
resistant P. aeruginosa or those who are intolerant to
tobramycin. Longitudinal NAG measurements may be useful
in patients with CF, especially those with CFRD, to identify
patients at risk of developing renal disease.References
[1] Cystic Fibrosis Foundation Patient Registry. Annual Data Report 2004.
Bethesda, MD: Cystic Fibrosis Foundation; 2005.
[2] UKCF Database. Annual Data Report. Data Returns and Survey 2003,
February 2005 © University of Dundee.
[3] Kovesi TA, Swartz R, McDonald N. Transient renal failure due to
simultaneous ibuprofen and aminoglycoside therapy in children with
cystic fibrosis. N Engl J Med 1998;64:65–6.
[4] Drew JH, Watson AR, Evans JH, Smyth AR. Antibiotics and acute renal
failure in children with cystic fibrosis. Pediatr Perinat Drug Ther
2002;5:65–7.
[5] Drew J, Watson AR, Smyth A. Acute renal failure and cystic fibrosis.
Arch Dis Child 2003;88:646.
[6] Stephens SE, Rigden SPA, Price J. Acute renal failure (ARF) in cystic
fibrosis patients treated with ceftazidime and gentamicin in combina-
tion. Arch Dis Child 2001;84(Suppl 1):A52.
[7] Kennedy SE, Henry RL, Rosenberg AR. Antibiotic related renal failure
and cystic fibrosis. J Pediatr Child Health 2005;41(7):382–3.
[8] Scott CS, Retsch-Bogart GZ, Henry MM. Renal failure and vestibular
toxicity in an adolescent with cystic fibrosis receiving gentamicin and
standard dose ibuprofen. Pediatr Pulmonol 2001;31:314–6.
[9] Al-Aloul M, Miller H, Stockton P, Ledson MJ, Walshaw MJ. Acute
renal failure in CF patients chronically infected by the Liverpool
epidemic Pseudomonas aeruginosa strain (LES). J Cystic Fibros
2005;4:197–201.
[10] Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw
MJ. Renal impairment in cystic fibrosis patients due to repeated
intravenous aminoglycoside use. Pediatr Pulmonol 2005;39(1):15–20.
[11] Kunin CM, Chesney RW, Craig WA, England AC, DeAngelis C.
Enzymuria as a marker of renal injury and disease: studies of N-acetyl-
b-D-glucosaminidase in the general population and in patients with
renal disease. Pediatrics 1978;62:751–60.
[12] Watanabe K, Kojima K, Fukuda J, Ohbayasi K, Kobayashi T, Iwase S.
Reliability of urinary N-acetyl-b-D-glucosaminidase as an indicator of
renal tubular damage in neonates. Biol Neonate 1987;52:16–21.
[13] Raab WP. Diagnostic value of urinary enzyme determinations. Clin
Chem 1972;18:5–25.
[14] Csathy L, Pocsi I. Urinary N-acetyl-b-D-glucosaminidase determina-
tion in newborns and children: methods and diagnostic applications.
Eur J Clin Chem Clin Biochem 1995;33:575–87.
[15] Bosomworth MP, Aparicio SR, Hay AWM. Urine N-acetyl-b-D-
glucosaminidase—a marker of tubular damage? Nephrol Dial Transplant
1999;14:620–6.
73C. Etherington et al. / Journal of Cystic Fibrosis 6 (2007) 67–73[16] Reed MD, Vermeulen MW, Stern RC, Cheng PW, Powell SH, Boat TF.
Are measurements of urine enzymes useful during aminoglycoside
therapy? Pediatr Res 1981;15:1234–9.
[17] Steinkamp G, Lutge M, Wurster U, Schulz-Baldes JG, Grone HJ,
Ehrich JHH. Renal function in cystic fibrosis: proteinuria and
enzymuria before and after tobramycin therapy. Eur J Pediatr
1986;145:526–31.
[18] Godson C, Ryan MP, O'Halloran D, Bourke S, Brady HR, Fitzgerald
MX. Investigation of aminoglycoside nephrotoxicity in cystic fibrosis
patients. Scand J Gastroenterol 1988;143:70–3.
[19] Glass S, Plant ND, Spencer DA. The effects of intravenous tobramycin
on renal tubular function in children with cystic fibrosis. J Cyst Fibros
2005;4:221–5.
[20] Smyth A, Tan K, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D,
et al. Once versus three times daily regimens of tobramycin treatment for
pulmonary exacerbations of cystic fibrosis—the TOPIC study: a
randomised controlled trial. Lancet 2005;365:573–8.
[21] Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM.
Evaluation of a new definition for chronic Pseudomonas aeruginosa
infection in cystic fibrosis patients. J Cyst Fibros 2003;2(1):29–34.
[22] World Health Organisation. Definition, diagnosis and classification of
diabetes mellitus and its complications. Geneva: World Health
Organisation, Department of Non Communicable Disease Surveil-
lance; 1999.
[23] UK Cystic Fibrosis Trust Antibiotic Group. Antibiotic treatment for
cystic fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic
Group. Second edition. London: UK CF Trust; 2002.
[24] National Institute for Clinical Excellence. Management of type 2
diabetes. Renal disease—prevention and early management. Clinical
guideline F. London: National Institute for Clinical Excellence; 2002.
[25] Yuen CT, Price RG, Chattagoon L, Richardson AC, Praill PFG.
Colourimetric assays for N-acetyl-b-D-glucosaminidase and b-D-
galactosidase in human urine using newly developed w-nitrosyryl
substrates. Clin Chim Acta 1982;124:195–204.
[26] PPR Diagnostics Ltd. 7 Ivory Tower, London. E1W 1AT.[27] Jaffe M. Ueber den Neiderschlag, welchen Pikrinsaeure in noralen
Harn erzeugt and ueber eine neue Reaktion des Kreatinins. Z Physiol
Chem 1886;10:391–400.
[28] Roche Diagnostics Ltd. Bell Lane, Lewes, Sussex. BN7 1LG.
[29] Schindler R, Radke C, Paul K, Frei U. Renal problems after lung
transplantation of cystic fibrosis patients. Nephrol Dial Transplant
2001;16:1324–8.
[30] Samaniego-Picota MD, Whelton A. Aminoglycoside-induced nephro-
toxicity in cystic fibrosis: a case presentation and review of the
literature. Am J Ther 1996;3:248–57.
[31] Tune BM, Reznik VM, Mendoza SA. Renal complications of drug
therapy. In: Holliday MA, Barratt TM, Avner ED, editors. Pediatric
nephrology. Baltimore: Williams & Wilkins; 1994. p. 1212–26.
[32] Alestig K, Trollfors B, Andersson R, et al. Ceftazidime and renal
function. J Antimicrob Chemother 1984;13:177–81.
[33] Conway SP, PondMN,Watson A, Etherington C, Robey HL, Goldman
MH. Intravenous colistin sulphomethate in acute respiratory exacer-
bations in adult patients with cystic fibrosis. Thorax 1997;52
(11):987–93.
[34] Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw
MJ. Four years' experience of intravenous colomycin in an adult cystic
fibrosis unit. Eur Respir J 1998;12:592–4.
[35] Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, et al.
Steady-state pharmacokinetics of intravenous colistin methanesulpho-
nate in patients with cystic fibrosis. J Antimicrob Chem
2003;52:987–92.
[36] Whitehead A, Conway SP, Etherington C, Caldwell N, Dave J,
Sedgefield N. Efficacy and safety of once daily tobramycin in treating
acute respiratory exacerbations in adult patients with CF. Neth J Med
1999;54(Suppl 1):S36.
[37] Gibb DM, Tomlinson PA, Dalton NR, Turner C, Shah V. Renal tubular
proteinuria and microalbuminuria in diabetic patients. Arch Dis Child
1989;64:129–34.
[38] Stephens SE, Rigden SPA. Cystic fibrosis and renal disease. Paediatr
Respir Rev 2002;3:135–8.
